Illumina (ILMN) Peer Comparison
$279.47
$8.43
(3.11%)
As on 27-Oct-2026 16:10EDT
Market cap
$40,682 Mln
Revenue (TTM)
$4,493 Mln
P/E Ratio
50.3
P/B Ratio
13.2
Div. Yield
0 %
Edit
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
40,682 | 250,149 | 179,441 | 161,511 | 159,784 |
Revenue ($ Mln) |
4,493 | 47,351 | 48,229 | 25,608 | 11,578 |
Net Profit ($ Mln) |
825.00 | 7,083.00 | 4,701.00 | 4,331.00 | 2,957.20 |
Net Margin (%) |
18.36 | 14.96 | 9.75 | 16.91 | 25.54 |
RoE (%) |
29.67 | 13.25 | 18.06 | 8.13 | 17.59 |
Price to Earnings |
50.26 | 36.61 | 38.55 | 38.04 | 54.69 |
Price-To-Book |
13.17 | 4.67 | 3.58 | 2.96 | 7.82 |
Income Statement ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4,493.00 | 47,351.00 | 48,229.00 | 25,608.00 | 11,578.00 |
|
Cost of Revenue
|
1,492.00 | 27,729.00 | 20,681.00 | 10,603.00 | 3,798.50 |
|
Gross Profit
|
2,893.00 | 18,239.00 | 24,607.00 | 14,970.00 | 6,642.30 |
|
Operating Expenses
|
2,059.00 | 11,106.00 | 20,197.00 | 9,787.00 | 4,495.40 |
|
Operating Profit (EBIT)
|
942.00 | 8,515.00 | 7,351.00 | 5,218.00 | 3,284.10 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
1,015.00 | 7,869.00 | 6,562.00 | 4,818.00 | 3,619.00 |
|
Provision for Tax
|
190.00 | 742.00 | 1,861.00 | 487.00 | 645.90 |
|
Profit after Tax (Net Income)
|
825.00 | 7,083.00 | 4,701.00 | 4,331.00 | 2,957.20 |
|
Minority Interest
|
0.00 | -16.00 | 0.00 | 0.00 | -14.30 |
|
Consolidated Profit
|
484.00 | 1,964.00 | 1,776.00 | 1,197.00 | 0.00 |
Liabilities ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,838.00 | 54,767.00 | 0.00 | 53,621.00 | 15,986.20 |
|
Minority Interest
|
0.00 | -16.00 | 0.00 | 0.00 | -14.30 |
|
Non-Current Liabilities
|
2,234.00 | 45,296.00 | 0.00 | 30,610.00 | 698.30 |
|
Current Liabilities
|
1,578.00 | 14,170.00 | 0.00 | 9,050.00 | 2,533.00 |
|
Total Liabilities
|
6,644.00 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
Assets ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
3,816.00 | 88,618.00 | 0.00 | 78,494.00 | 10,920.80 |
|
Current Assets
|
2,834.00 | 25,615.00 | 0.00 | 14,787.00 | 8,428.30 |
|
Total Assets
|
6,644.00 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
|
Total Debt*
|
2,527.00 | 41,370.00 | 0.00 | 26,482.00 | 0.00 |
|
Net Current Assets
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cashflow ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,079.00 | 7,818.00 | 9,566.00 | 6,416.00 | 3,030.50 |
|
Cash Flow from Investing Activities
|
-55.00 | -4,047.00 | -2,422.00 | -1,196.00 | 665.80 |
|
Cash from Financing Activities
|
-744.00 | 1,801.00 | -6,309.00 | -2,961.00 | -2,364.10 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
16.55 | 7.69 | 10.03 | 5.25 | 16.46 |
|
ROE (%)
|
29.67 | 13.25 | 18.06 | 8.13 | 17.59 |
|
ROA (%)
|
9.69 | 5.50 | 9.52 | 4.46 | 12.09 |
|
EBIT Margin (%)
|
24.26 | 13.63 | 11.82 | 15.27 | 24.79 |
|
Net Margin (%)
|
18.36 | 14.96 | 9.75 | 16.91 | 25.54 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
4.93 | 8.27 | 10.00 | 5.52 | 20.45 |
|
EBIT Growth (%)
|
-27.62 | -24.37 | -34.24 | -12.03 | -9.33 |
|
Net Profit Growth (%)
|
-34.42 | 7.81 | -66.37 | 23.64 | 7.66 |
|
EPS Growth (%)
|
-32.04 | 9.68 | -66.31 | 26.16 | 9.30 |
|
Book Value Growth (%)
|
28.97 | 9.37 | -- | 6.02 | -2.83 |
Valuation Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
23.76 | 32.43 | 33.55 | 45.04 | 71.47 |
|
Price / Book Value
|
7.42 | 4.09 | 4.20 | 3.10 | 11.45 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
14.49 | 21.61 | 18.87 | 25.42 | 49.76 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.29 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.21 | 0.04 | 0.06 | 0.04 | 0.00 |
|
Current Ratio
|
1.80 | 1.81 | 1.58 | 1.63 | 3.33 |
|
Quick Ratio
|
1.40 | 1.41 | 1.18 | 1.29 | 2.49 |
|
Interest Coverage
|
14.53 | 6.12 | 8.37 | 14.38 | -- |
Operating Efficiency Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.00 | 20.33 | 0.00 | 20.02 | 14.87 |
|
Asset Turnover
|
0.53 | 0.37 | 0.98 | 0.26 | 0.47 |
|
Receivable days
|
67.57 | 82.76 | 61.20 | 61.72 | 54.16 |
|
Inventory Days
|
140.41 | 72.19 | 117.44 | 91.69 | 177.54 |
|
Payable days
|
58.26 | 46.50 | 78.11 | 68.44 | 23.93 |
|
Cash Conversion Cycle
|
149.72 | 108.45 | 100.53 | 84.97 | 207.78 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
